Fennec Pharmaceuticals In...

5.64
-0.30 (-5.05%)
At close: Apr 03, 2025, 3:59 PM
5.85
3.68%
After-hours: Apr 03, 2025, 07:16 PM EDT

Company Description

Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company.

Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients.

The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014.

Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc. logo
Country United States
IPO Date Sep 15, 2017
Industry Biotechnology
Sector Healthcare
Employees 32
CEO Jeffrey S. Hackman

Contact Details

Address:
68 TW Alexander Drive
Research Triangle Park, North Carolina
United States
Website https://www.fennecpharma.com

Stock Details

Ticker Symbol FENC
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001211583
CUSIP Number 31447P100
ISIN Number CA31447P1009
Employer ID 00-0000000
SIC Code 2836

Key Executives

Name Position
Jeffrey S. Hackman Chief Executive Officer & Director
Robert C. Andrade Chief Financial Officer
Christiana Cioffi M.B.A. Chief Strategy Officer
Dr. Pierre S. Sayad M.S., Ph.D. Chief Medical Officer
Lei Fang President of Pharstat Inc
Mark Gowland Controller
Terry Evans Chief Commercial Officer

Latest SEC Filings

Date Type Title
Apr 01, 2025 4 Filing
Apr 01, 2025 4 Filing
Mar 26, 2025 10-K Annual Report
Mar 10, 2025 8-K Current Report
Mar 06, 2025 4 Filing
Feb 28, 2025 4 Filing
Feb 28, 2025 4 Filing
Feb 14, 2025 4 Filing
Feb 14, 2025 SCHEDULE 13G/A [Amend] Filing
Feb 14, 2025 SCHEDULE 13G/A [Amend] Filing